Quotes 5-day view Delayed Nyse
09/14/2020
09/15/2020
09/16/2020
09/17/2020
09/18/2020
Date
90.49(c)
90.91(c)
89.78(c)
89.63(c)
90.11(c)
Last
5 212 480
3 851 321
6 307 956
5 604 683
9 996 405
Volume
+0.88% +0.46% -1.24% -0.17% +0.54% Change
Sales 2020
45 502 M - -
Net income 2020
10 949 M - -
Net Debt 2020
71 972 M - -
P/E ratio 2020
16,3x
Yield 2020
5,42%
Sales 2021
53 597 M - -
Net income 2021
15 922 M - -
Net Debt 2021
60 538 M - -
P/E ratio 2021
10,4x
Yield 2021
5,76%
Capitalization
159 B 159 B -
EV / Sales 2020
5,08x
EV / Sales 2021
4,10x
Nbr of Employees
47 000
Free-Float
98,5%
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Sales are distributed geographically as follows: the United States (71.9%), Japan (3.7%), Germany...
Notations Surperformance© of AbbVie Inc.
Trading Rating : Investor Rating :
All news about ABBVIE INC.
News in other languages on ABBVIE INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ABBVIE INC.
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
18
Average target price
109,56 $
Last Close Price
90,11 $
Spread / Highest target
40,9%
Spread / Average Target
21,6%
Spread / Lowest Target
6,54%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
